Biopharma spending on drug research is climbing, even as the projected revenue for those products is falling. According to consultancy Deloitte, various factors are at fault, but the biggest ones but the biggest one is the adjustment an industry is making to a post-pandemic environment.
Category Archive: Business of the drug industry
A “cancer moonshot” refers to an ambitious effort to accelerate progress in cancer research and treatment, drawing inspiration from the determination and focus that drove the United States moon landing in 1969. While eradicating cancer may be a monumental task, significant advancements have been made in understanding and treating various types of cancer.
The exact cause of Alzheimer’s disease is not yet fully understood. However, extensive research has shed light on several factors contributing to its development, so we need to see ALL the data on Lilly’s new drug.
Mounjaro, already on the market to treat Type 2 diabetes in the U.S., is going head to head with Novo’s drug. The stakes are enormous in need, expected to be over $30 billion by 2030, according to analysts at Cowen Inc. Novo Nordisk was projected to capture the largest share, with Wegovy sales topping $7 billion, but if Lilly’s head-to-head trials turn out well Mounjaro, and Lilly, could be huge winners.
Obesity drug hype is finally subsiding, according to buzz metrics I follow, but too many in the media have failed to address critical issues of weight loss drugs. From my research HCPs are finally starting to ask hard questions about the use of these drugs.
The Biden administration said it would penalize drugmakers for raising prices faster than inflation on 27 medications administered in doctors’ offices. Pfizer had the most drugs on the list, which includes AbbVie for its blockbuster rheumatoid arthritis drug, Humira, as well as manufacturers Gilead, Endo, Leadiant Biosciences, and Kamada.
The private healthcare industry is enormous, notoriously challenging to navigate, and making a lot of money at the expense of the public. The industry enjoys massive profits, often by undermining public programs and exploiting patents, whose ruthless pursuit of money usually has life-threatening consequences. It maybe time to end for-profit healthcare.
The FDA calls drug approval a “balancing act” between acceptable risks and benefits on its website. The FDA’s approval process may favor drug companies over consumers, and FDA approval does not guarantee safety. Big Pharma pays for the majority of drug safety reviews, provides the FDA with safety data for the review and has the option to have drugs approved faster with fewer clinical trials.